Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1986-10-8
pubmed:abstractText
Syrian hamster embryo cells transformed by adenovirus type 2 (Ad2) or simian virus 40 (SV40) differ markedly in morphology, tumorigenicity, and susceptibility to in vitro lysis by nonspecific cytotoxic cells. Hybrid cells formed by fusing Ad2- and SV40-transformed Syrian hamster embryo cells may express only SV40 T antigens or both SV40 and Ad2 T antigens. Hybrids that express only SV40 T antigens are indistinguishable from the nonhybrid SV40-transformed phenotype, whereas hybrid cells that express T antigens from both viruses closely resemble the nonhybrid parental Ad2-transformed phenotype. Because these hybrid cells have been useful in the study of neoplastic transformation, we determined the amount of viral antigens that they accumulate in an attempt to correlate the level of expression of the transforming viral genes with some of their phenotypic properties. Hybrid cells that expressed proteins from both viruses showed reduced levels of SV40 T antigens compared with those of hybrid cells that did not express Ad2 T antigens. We also found that the production of several cellular proteins that influence cytomorphology was inhibited in hybrid and nonhybrid cells that expressed Ad2 T antigens, and the repression of these cellular proteins correlated with a change in cytomorphology from fibroblastic to spherical. Finally, we showed that the susceptibility of our hybrid cells to in vitro lysis by natural killer cells and activated macrophages, two putative host-effector cells involved in defense against neoplasia, correlated closely with the level of expression of a 58,000-dalton Ad2 protein. The results reported here, together with the results of previous studies, indicate that the oncogenic potential of hybrid cells that express both Ad2 and SV40 antigens is extremely sensitive to Ad2 expression, whereas other phenotypic properties depend on Ad2 expression in a dose-dependent manner.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-1068469, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-1242069, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-169093, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-2982503, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-326414, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-3843807, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-427789, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-4364901, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-5432063, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-568181, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6091106, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6091899, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6095113, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6242485, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6248874, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6267583, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6277479, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6283358, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6298123, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6303562, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6310610, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6311432, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6330996, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6355856, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6467201, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6580645, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6605479, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6606259, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6611509, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-6686086, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-7332929, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-7352373, http://linkedlifedata.com/resource/pubmed/commentcorrection/3018533-942051
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0270-7306
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1870-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
The level of expression of adenovirus type 2 transforming genes governs sensitivity to nonspecific immune cytolysis and other phenotypic properties of adenovirus 2-simian virus 40-transformed cell hybrids.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't